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T 
he actions ofproinflammatory or regulatory cytokines 
have been quite unpredictable when expressed individu- 
ally within tissues such as in transgenic mice. Cytokines that 
have been considered proinflammatory in the classical sense 
have been shown to have immunosuppressive effects; like- 
wise, cytokines that have demonstrated immunosuppressive 
activity have proven to be proinflammatory in these trans- 
genic experimental systems (1). In this issue, studies on elici- 
tation  of the  cytokine  tumor  necrosis  factor-0~  (TNF-o  0 
within  the  context  of pancreatic  islets  elegantly  illustrate 
this  paradox  (2).  The  proinflammatory cytokine  TNF-cx, 
long  associated  with  phenomena  such  as  autoimmunity, 
cell death, and cachexia shows quite unexpected character- 
istics  in this transgenic system. In the current study, it was 
demonstrated that within  the  limited  context  of the  pan- 
creatic islets,  TNF-o~ prevents the development of diabetes 
in the most widely studied animal model of the spontane- 
ous  disease:  the  nonobese  diabetic  (NOD)  mouse.  This 
work is important for several additional reasons other than 
the unpredicted ability of this cytokine to divert the nearly 
inevitable  autoimmune  responses  that  mediate  disease  in 
the NOD mouse. The data presented in this paper support 
a unique mechanism of disease  amelioration, although a full 
picture will have to await additional studies. 
Previous work by these authors with the identical trans- 
gene harbored by nondiabetes-prone mice has highlighted 
the  proinflammatory nature  of TNF-ci because the  cyto- 
kine was demonstrated to induce inflammation and leuko- 
cyte extravasation in these  animals  (3).  This was probably 
mediated through the induction of adhesion molecules that 
support leukocyte extravasation into the pancreas.  Insulitis 
resulted and progressed to be quite severe. Although these 
lymphocytes traffic in large numbers into  the  islet region, 
they are unable to promote killing of sufficient numbers of 
beta cells to induce any hyperglycemia despite their ability 
to  cross into  the  actual islet parenchyma core and disrupt 
the  islet  architecture.  Thus,  on  a  nonsusceptible  genetic 
background, severe infiltration does not promote disease. 
TNF-oe Leads to a Defect in Priming of Potentially 
Autoreactive  T  Cells 
In the context of a diabetes susceptible MHC haplotype 
and additional genetic factors that promote a high sponta- 
neous  disease  incidence,  the  transgene  reveals the  cryptic 
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but powerfial immunosuppressive ability of the TNF-ci mole- 
cule (2). The mechanism of this cytokine's effect within the 
pancreas is still somewhat mysterious, although the current 
publication provides some important clues to what under- 
lies  its  immunosuppression.  The  most striking finding  in 
the TNF-cx-protected mice is the lack of T  cell responses 
to  individual  islet  antigens  or  to  whole  islet  extracts,  to 
which  the  nontransgenic  diabetes-prone  NOD  mice  re- 
spond vigorously. The authors  have ruled out generalized 
systemic immunosuppression through experiments demon- 
strating normal responses to the exogenous antigen KLH in 
their transgenic model. Thus, the transgene confers a spe- 
cific defect in the ability to prime and activate potentially 
diabetogenic  T  cells  in the pancreas or,  more profoundly, 
can specifically and permanently inactivate these potential 
clones in situ. Alterations in islet antigenicity or accessibil- 
ity do  not explain the  observed protection as  emphasized 
by experiments where  diabetogenic T  cells  are transferred 
into  the  transgenic  mice,  causing rapid beta  cell loss  and 
disease.  Refreshingly, the observed protection does not ap- 
pear to be mediated by a shift in functional specialization 
toward the Th2 phenotype, a now universally applied para- 
digm,  since  cytokine  profiles  to  islet  antigens  were  not 
found to contain a predominance of IL-4. Taken together, 
the evidence supports an alteration ofT cell priming within 
the  pancreatic  vicinity  of TNF-oL  transgenic  mice.  Sup- 
porting this notion are the related experiments performed 
in double-transgenic nondiabetes-prone mice showing that 
coexpression of the  B7-1  costimulatory molecule by TNF- 
oL-producing [3 cells leads to their destruction (4). 
A  more complete understanding  of the  events that lead 
to the priming of a diabetogenic T  cell in disease-suscepti- 
ble individuals  may be necessary to  comprehend fully the 
mechanism of protection in the current transgenic model. 
The recent surge in interest in CD8  cells as initiators  of 
[3 cell damage in the NOD mouse (5) could, in the current 
context,  implicate a signaling change in the  [3  cells  them- 
selves that is responsible for sending alternative messages to 
antigen-specific T  cells  that  enter the  islet,  as the  authors 
suggest.  These T  cells  could fail to become primed or be 
rendered permanently inactive  (anergic)  by the  transgenic 
TNF-o~-producing 13 cell and therefore unable to perpetu- 
ate the  cascade of events that result in sensitization in the 
CD4 compartment, determinant spreading,  and the subse- 
quent effector phase,  during which the majority of the [3 cells 
are destroyed. 
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pressive activities of TNF are enacted through other interme- 
diary cells whose function is to prime potentially diabetogenic 
T  cells within the islet vicinity. These islet-associated anti- 
gen-presenting  cells  (dendritic  cells,  macrophages,  or  B 
cells) could be affected in a variety of subtle ways that alter 
the course of T  cell priming. While altered chemotaxis of 
any individual antigen-presenting cell category was not ob- 
served by the authors,  altered antigen-presenting function 
has yet to be assessed.  This type of shift in function could 
be enacted through a TNF-cx effect on antigen processing, 
transport, or presentation. Significantly, a recent elegant re- 
port  demonstrates  that  TNF-ot  is  extremely inhibitory  to 
the ability of dendritic  cells  to present soluble antigen  (6). 
This effect is mediated by a down regulation of the invari- 
ant chain (Ii) and the FcyRII of the dendritic cells, although 
surface expression of MHC class II is increased.  Dendritic 
cells  are  scattered in  tissues  (such  as  pancreatic  islets)  and 
pick up  and process soluble antigens;  therefore,  they may 
play  a  pivotal  role  in  mediating  the  pathogenic  priming 
events that precede islet recognition and autoimmune dia- 
betes  (7).  When  exposed  to  TNF-R  these  cells  may  no 
longer be able to prime potentially islet-autoreactive T  cells. 
Such a mechanism may explain the lack of reactivity to islet 
cell antigens and extracts that was observed in the current 
study using TNF-ot transgenic mice, and the ability of cells 
primed in the absence of the transgene to mediate disease 
when introduced by adoptive transfer into transgenic mice. 
It should  be  mentioned  that  other  collaborative,  albeit 
nonimmune mechanisms could enhance  the  apparent im- 
munosuppressive properties of TNF-o~ in the pancreas. For 
example, localized expression of TNF-ot has been demon- 
strated  to lead  to  the  development of limited numbers of 
ductal  endocrine  cells  (8).  These  ductal  endocrine  ceils 
could have altered antigenic specificity and thus be unable 
to become targets for any remaining immune response, yet 
secrete  enough  insulin  to  prevent development of hyper- 
glycemia. Additionally,  TNF-o~ inhibits  signaling through 
the  insulin  receptor,  and  therefore  is  associated  with  the 
development of a state of insulin resistance such as observed 
in non-insulin  dependent  diabetes mellitus  (NIDDM)  (9). 
In the transgenic mice, the resulting superimposition of the 
characteristics of NIDDM with increased insulin levels due 
to lack of clearance and oflDDM might lead to a state of ]3 
cell  rest,  which  has  been long associated with  protection 
from immune-mediated destruction. 
Disparities  between Local and Systemic Mechanisms 
of Immunosuppression 
The authors of the TNF-0~ work relate their findings to 
earlier interesting  and  enigmatic work demonstrating that 
diabetes and insulitis were inhibited in NOD mice by sys- 
temic  treatment  with  TNF-oL  (10).  The  observation  of 
these authors was that treatment of adult NOD mice with 
TNF-o~ will substantially delay spontaneous IDDM. More 
recent work illustrates the complexity of  such systemic studies, 
because parallel experiments using very young NOD mice 
resulted in acceleration of clinical disease  (11). These super- 
ficially  contradictory  results  underscore  the  fact  that  the 
early and late events that  occur during  the progression to 
clinical disease  in NOD  mice are separable and subject to 
distinct  regulatory mechanisms.  Moreover,  the  mechanism 
of TNF-0~ action when  studied  in  transgenic mice where 
the  molecule  is  produced  constitutively  in  the  pancreas 
need not be related  to  the  explanation  of protection  that 
was observed with systemic treatment.  This is because the 
hierarchy of events that precedes [3 cell destruction in islets 
includes processes such as T  cell development, thymic selec- 
tion, and homing to peripheral lymphoid organs,  which  are 
all  subject  to  multiple  levels  of counterregulation.  Thus 
stems the  truly troubling  paradox  that  in  some  cases  sys- 
temic treatment with either the cytokine or its neutralizing 
antibody lead to the equivalent net biological effect (11-13). 
In  the  early TNF-o~ treatment  acceleration  model,  the 
previously described action of TNF-ot in the thymus (14), for 
example, could alter the available pool of islet-reactive T  cells 
in these systemic studies or, alternatively, its effect on lym- 
phoid organ development could enhance the necessary es- 
tablishment of vascular structures that support lymphocyte 
extravasation.  Prevention  of disease  in  the  adult  NOD 
mouse by systemic administration  appears to be associated 
with a lack of infiltration of the pancreas. This could be ac- 
counted for by lymphopenia or by altered homing proper- 
ties  brought  about by changes  in  adhesion  capabilities  of 
circulating leukocytes. These mechanisms could not easily 
account for the observations in the localized TNF-e~-express- 
ing transgenic model. 
Prospects and Perspectives on Localized Immunoprotection: 
TNF-ce versus IL-4 
The ability to modulate the responsiveness or immuno- 
logical accessibility of an individual tissue has profound im- 
plications for therapy, applicable to a variety of situations. It 
is generally accepted that most regulatory cytokines are far 
too toxic for systemic use in humans. Thus, the demonstra- 
tion of efficacy in animal models of localized elicitation of 
cytokines is an important new advance for the design and 
execution  of gene therapy delivery protocols.  Thus far in 
the  NOD  diabetes  model,  both  IL-4  and  TNF-0~  have 
shown profound efficacy in eliminating destructive autoim- 
mune responses to islets  (2,  15).  Additionally,  IL-4 expres- 
sion by islets  can induce  a permanent state of tolerance to 
engrafted syngeneic islet cells,  and block the effect of dia- 
betogenic lymphocytes following adoptive transfer.  Func- 
tional immunological tolerance as demonstrated by synge- 
neic islet grafts may also be induced by TNF-o~, because anti- 
islet responses were diminished in the TNF-ot transgenic mice 
and therefore syngeneic grafts may survive in this strain as 
well. 
However, it is important to note that the available data 
suggests that these two cytokine transgenics reflect funda- 
mentally different underlying mechanisms of protection (2, 
15).  This is best illustrated by two sets  of comparative ex- 
perimental results.  First,  splenocytes  from IL-4 transgenic 
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transgenics will not.  This critical distinction reflects an in- 
ability to prime diabetogenic  T  cells  in  the pancreatic vi- 
cinity of TNF-o~ transgenics,  while in the IL-4 transgenic 
mice T  cells do become primed with diabetes relevant anti- 
gens.  Second,  pancreatic  IL-4 will prevent diabetes when 
diabetogenic  spleen  cells  from nontransgenic  NOD  mice 
are introduced,  while  the TNF-o~ transgenics  succumb to 
disease.  This implies that  IL-4 elicitation mediates regula- 
tion through activated T  cell specificities within natural di- 
abetogenic  repertoire,  while  localized  TNF-ci  allows  no 
such activated repertoire to be established. Therefore, IL-4 
may have regulatory capability during both the initial and 
ongoing phases of the disease process, while TNF-o~ com- 
pletely blocks disease  initiation. 
The  use  of the  now well-established  methods  of gene 
transfer through a variety of viruses (retrovirus, adenovirus, 
and lentivirus)  therefore should facilitate the protection of 
individual tissues  from autoimmune-mediated damage (16, 
17).  Similarly, these molecules have the potential to modu- 
late the localized immune response to the decidedly more 
vigorous and rapid immunity to  allografts and xenografts, 
affording  the  potential  for  localized  immunoprotection, 
which is highly advantageous to systemic immunosuppres- 
sion.  The  most powerful  approach,  clearly,  is  to  position 
the cytokine within the islets themselves, as providing IL-4- 
expressing T  cells does not lead to any protection from im- 
mune mediated damage, possibly owing to  the  transience 
of the signal within the islets  (18).  Thus, such an approach 
could only be applied to a short-term acute situation.  The 
ability to regulate expression of these factors using induc- 
ible elements within promoters will increase the ability to 
regulate the specific phases of these complex autoimmune 
phenomenon. 
Tissue  Tropisms: Additional Complexities  in 
Localized Immunoregulation 
Part  of the  unpredictability  of the  actions of individual 
inflammatory mediators comes from the fact that many of 
their properties  have been  characterized in  using in vitro 
culture  systems.  In  the  body,  of course,  these  factors are 
elicited  within  lymphoid  organs  and  in  tissues,  during  an 
inflammatory  response.  Recent  observations  suggest  that 
the  action  of these factors are modulated in part by other 
collaborating signals present within tissues.  Thus, the iden- 
tical individual signal in two tissues  can lead to a very dif- 
ferent immunologic outcome. This has been observed with 
transgenic expression of IFN-g, which elicits  cell-mediated 
immune destruction in the absence of humoral response in 
the  pancreatic  compartment (19,  20)  compared with  hu- 
moral autoimmunity and the  absence of evidence of cell- 
mediated damage in the neuromuscular junction  (21).  The 
regulation of such distinct responses may be exerted by the 
category of immune cells that reside in the tissue or appear 
when it becomes permeablized to inflammatory cells.  It is 
also  possible  that  antigen-presenting  cells  resident  within 
tissues  have mutually distinct pathways to respond to these 
mediators.  Some evidence for this  comes from the  subtly 
distinct response to TNF-o~ in Langerhans cells versus den- 
dritic  cells,  the former of which  downregulate MHC class 
II synthesis in response to TNF-o~, while the latter do not 
(6,  22).  Such  subtle  variation  of terminally  differentiated 
function could allow the possibility for distinct processing, 
presentation,  or activation capacities of antigen-presenting 
cells within tissues  when exposed to specific inflammatory 
mediators. This type of phenomenon may lead to vast dif- 
ferences  in  patterns  of T  cell  activation  or  even  altered 
functional specialization of activated T  cells, thus diversify- 
ing responses within individual tissue compartments. A fur- 
ther understanding of tissue tropisms will be important for 
predicting the outcome of cytokine-mediated immunopro- 
tection studies,  and will  eventually enhance  our ability to 
hide  individual pools  of antigen  that are targets in patho- 
genic responses to tissues from the autodestructive immune 
system. 
Thus, the ability to segregate a tissue compartment from 
immune-mediated surveillance and damage, while  sparing 
the organism from systemic immunosuppression, is increas- 
ingly within reach. Recent work utilizing transgenic tech- 
nology has raised significant hopes as to the overall applica- 
tion of this type of approach. As additional basic information 
regarding tissue tropisms will emerge, subtle differences in 
terminal differentiation of the regional immune system will 
be  discovered,  eventually  allowing  for  more  specialized 
compartment appropriate regulatory strategies. 
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